fluorouracil has been researched along with Response Evaluation Criteria in Solid Tumors in 37 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer." | 5.34 | Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. ( Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K, 2020) |
| "FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer." | 5.22 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. ( Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2016) |
| "The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC)." | 4.98 | Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Almeida, PHRF; Andrade, EIG; Cherchiglia, ML; da Silva, WC; de Araujo, VE; de Assis Acurcio, F; Dos Santos, JBR; Godman, B; Kurdi, A; Lima, EMEA; Silva, MRRD, 2018) |
| "The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC)." | 3.96 | Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. ( Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B, 2020) |
| "This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed." | 3.96 | Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. ( Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P, 2020) |
| " All patients were offered 3 months of induction chemotherapy (FOLFIRINOX or gemcitabine depending on performance status), followed by exploratory laparotomy for resection or IRE in patients with Response Evaluation Criteria in Solid Tumors (RECIST) 1." | 3.85 | Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. ( Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW, 2017) |
| "5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression." | 3.01 | Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). ( Aljumaily, R; Autio, KA; Bauer, TM; Bendell, J; Falchook, GS; Hecht, JR; Hung, A; Infante, JR; Javle, M; Leveque, J; Naing, A; Oft, M; Pant, S; Papadopoulos, KP; Patel, MR; Rao, S; Ratti, N; VanVlasselaer, P; Verma, R; Wainberg, ZA; Wong, DJ, 2021) |
| "This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma." | 2.94 | Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. ( Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020) |
| "However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis." | 1.62 | Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. ( Ye, Y; Zheng, S, 2021) |
| "Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3-5) and three (IQR 3-5) cycles respectively." | 1.62 | Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. ( Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW, 2021) |
| "Historically, biliary tract cancer (BTC) and pancreatic cancer have been treated similarly with gemcitabine alone or combined with a platinum compound." | 1.56 | A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. ( Almohamad, W; Biondani, P; Chebib, A; Ciacio, O; Gumus, Y; Haydar, M; Innominato, PF; Karaboué, A; Pittau, G; Ulusakarya, A, 2020) |
| "Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival." | 1.48 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018) |
| "The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified." | 1.48 | Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. ( de Miguel-Pérez, D; Delgado-Ramirez, M; Delgado-Ureña, M; Exposito-Hernandez, J; García-Puche, JL; Garrido-Navas, MC; Ilyine, H; Lorente, JA; Ortega, FG; Rodriguez-Martínez, A; Serrano, MJ, 2018) |
| "Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance." | 1.46 | Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. ( Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J, 2017) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| " Most adverse events were mild (grade 1-2) (Common Terminology Criteria for Adverse Events, version 3." | 1.42 | Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ( Kumita, S; Mine, T; Murata, S; Onozawa, S; Sakamoto, A; Sugihara, F; Ueda, T; Yamaguchi, H; Yasui, D, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (54.05) | 24.3611 |
| 2020's | 17 (45.95) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Y | 1 |
| Zheng, S | 1 |
| Chapalain, M | 1 |
| Baroudjian, B | 1 |
| Dupont, A | 1 |
| Lhote, R | 1 |
| Lambert, J | 1 |
| Bagot, M | 1 |
| Lebbe, C | 1 |
| Basset-Seguin, N | 1 |
| Hammel, P | 1 |
| Fabienne, P | 1 |
| Mineur, L | 1 |
| Metges, JP | 1 |
| Andre, T | 1 |
| De La Fouchardiere, C | 1 |
| Louvet, C | 1 |
| El Hajbi, F | 2 |
| Faroux, R | 2 |
| Guimbaud, R | 2 |
| Tougeron, D | 1 |
| Bouche, O | 2 |
| Lecomte, T | 2 |
| Rebischung, C | 1 |
| Tournigand, C | 1 |
| Cros, J | 1 |
| Kay, R | 1 |
| Hamm, A | 1 |
| Gupta, A | 1 |
| Bachet, JB | 1 |
| El Hariry, I | 1 |
| Lu, W | 1 |
| Fu, D | 1 |
| Kong, X | 1 |
| Huang, Z | 1 |
| Hwang, M | 1 |
| Zhu, Y | 1 |
| Chen, L | 1 |
| Jiang, K | 1 |
| Li, X | 1 |
| Wu, Y | 1 |
| Li, J | 1 |
| Yuan, Y | 1 |
| Ding, K | 1 |
| Dercle, L | 1 |
| Lu, L | 1 |
| Schwartz, LH | 1 |
| Qian, M | 1 |
| Tejpar, S | 1 |
| Eggleton, P | 1 |
| Zhao, B | 1 |
| Piessevaux, H | 1 |
| O'Kane, GM | 1 |
| Grünwald, BT | 1 |
| Jang, GH | 1 |
| Masoomian, M | 1 |
| Picardo, S | 1 |
| Grant, RC | 1 |
| Denroche, RE | 1 |
| Zhang, A | 1 |
| Wang, Y | 1 |
| Lam, B | 1 |
| Krzyzanowski, PM | 1 |
| Lungu, IM | 1 |
| Bartlett, JMS | 1 |
| Peralta, M | 1 |
| Vyas, F | 1 |
| Khokha, R | 1 |
| Biagi, J | 1 |
| Chadwick, D | 1 |
| Ramotar, S | 1 |
| Hutchinson, S | 1 |
| Dodd, A | 1 |
| Wilson, JM | 1 |
| Notta, F | 1 |
| Zogopoulos, G | 1 |
| Gallinger, S | 1 |
| Knox, JJ | 1 |
| Fischer, SE | 1 |
| Yao, Y | 1 |
| Li, N | 1 |
| Wolfe, AR | 1 |
| Prabhakar, D | 1 |
| Yildiz, VO | 1 |
| Cloyd, JM | 1 |
| Dillhoff, M | 1 |
| Abushahin, L | 1 |
| Alexandra Diaz, D | 1 |
| Miller, ED | 1 |
| Chen, W | 1 |
| Frankel, WL | 1 |
| Noonan, A | 1 |
| Williams, TM | 1 |
| Ulusakarya, A | 1 |
| Karaboué, A | 1 |
| Ciacio, O | 1 |
| Pittau, G | 1 |
| Haydar, M | 1 |
| Biondani, P | 1 |
| Gumus, Y | 1 |
| Chebib, A | 1 |
| Almohamad, W | 1 |
| Innominato, PF | 1 |
| Hosokawa, A | 1 |
| Yamazaki, K | 1 |
| Matsuda, C | 1 |
| Ueda, S | 1 |
| Kusaba, H | 1 |
| Okamura, S | 1 |
| Tsuda, M | 1 |
| Tamura, T | 1 |
| Shinozaki, K | 1 |
| Tsushima, T | 1 |
| Tsuda, T | 1 |
| Shirakawa, T | 1 |
| Yamashita, H | 1 |
| Morita, S | 1 |
| Hironaka, S | 1 |
| Muro, K | 1 |
| Hecht, JR | 1 |
| Papadopoulos, KP | 1 |
| Falchook, GS | 1 |
| Patel, MR | 1 |
| Infante, JR | 1 |
| Aljumaily, R | 1 |
| Wong, DJ | 1 |
| Autio, KA | 1 |
| Wainberg, ZA | 1 |
| Bauer, TM | 1 |
| Javle, M | 1 |
| Pant, S | 1 |
| Bendell, J | 1 |
| Hung, A | 1 |
| Ratti, N | 1 |
| VanVlasselaer, P | 1 |
| Verma, R | 1 |
| Leveque, J | 1 |
| Rao, S | 1 |
| Oft, M | 1 |
| Naing, A | 1 |
| Froelich, MF | 1 |
| Petersen, EL | 1 |
| Heinemann, V | 2 |
| Nörenberg, D | 1 |
| Hesse, N | 1 |
| Gesenhues, AB | 1 |
| Modest, DP | 2 |
| Sommer, WH | 1 |
| Hofmann, FO | 1 |
| Stintzing, S | 2 |
| Holch, JW | 1 |
| Walma, MS | 1 |
| Brada, LJ | 1 |
| Patuleia, SIS | 1 |
| Blomjous, JG | 1 |
| Bollen, TL | 1 |
| Bosscha, K | 1 |
| Bruijnen, RC | 1 |
| Busch, OR | 2 |
| Creemers, GJ | 2 |
| Daams, F | 1 |
| van Dam, R | 1 |
| Festen, S | 1 |
| Jan de Groot, D | 1 |
| Willem de Groot, J | 1 |
| Mohammad, NH | 1 |
| Hermans, JJ | 1 |
| de Hingh, IH | 1 |
| Kerver, ED | 1 |
| van Leeuwen, MS | 1 |
| van der Leij, C | 1 |
| Liem, MS | 1 |
| van Lienden, KP | 2 |
| Los, M | 2 |
| de Meijer, VE | 1 |
| Meijerink, MR | 1 |
| Mekenkamp, LJ | 1 |
| Nederend, J | 3 |
| Nio, CY | 1 |
| Patijn, GA | 1 |
| Polée, MB | 1 |
| Pruijt, JF | 1 |
| Renken, NS | 1 |
| Rombouts, SJ | 2 |
| Schouten, TJ | 1 |
| Stommel, MWJ | 1 |
| Verweij, ME | 1 |
| de Vos-Geelen, J | 1 |
| de Vries, JJJ | 1 |
| Vulink, A | 1 |
| Wessels, FJ | 1 |
| Wilmink, JW | 2 |
| van Santvoort, HC | 1 |
| Besselink, MG | 2 |
| Molenaar, IQ | 1 |
| Tabernero, J | 1 |
| Bang, YJ | 1 |
| Van Cutsem, E | 1 |
| Fuchs, CS | 1 |
| Janjigian, YY | 1 |
| Bhagia, P | 1 |
| Li, K | 1 |
| Adelberg, D | 1 |
| Qin, SK | 1 |
| Rovers, KP | 1 |
| Bakkers, C | 1 |
| Nienhuijs, SW | 1 |
| Burger, JWA | 2 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| van Meerten, E | 1 |
| Tuynman, JB | 1 |
| Kusters, M | 1 |
| Versteeg, KS | 1 |
| Aalbers, AGJ | 1 |
| Kok, NFM | 1 |
| Buffart, TE | 1 |
| Wiezer, MJ | 1 |
| Boerma, D | 1 |
| de Reuver, PR | 1 |
| Bremers, AJA | 1 |
| Verheul, HMW | 1 |
| Kruijff, S | 1 |
| de Groot, DJA | 1 |
| Witkamp, AJ | 1 |
| van Grevenstein, WMU | 1 |
| Koopman, M | 1 |
| Lahaye, MJ | 1 |
| Kranenburg, O | 1 |
| Fijneman, RJA | 1 |
| van 't Erve, I | 1 |
| Snaebjornsson, P | 1 |
| Hemmer, PHJ | 1 |
| Dijkgraaf, MGW | 1 |
| Punt, CJA | 1 |
| Tanis, PJ | 1 |
| de Hingh, IHJT | 1 |
| Voogt, ELK | 1 |
| Schaap, DP | 1 |
| van den Berg, K | 1 |
| Nieuwenhuijzen, GAP | 1 |
| Bloemen, JG | 1 |
| Willems, J | 1 |
| Cnossen, JS | 1 |
| Peulen, HMU | 1 |
| van Lijnschoten, G | 1 |
| Rutten, HJT | 1 |
| Vogel, JA | 1 |
| de Rooij, T | 1 |
| van Delden, OM | 1 |
| Dijkgraaf, MG | 1 |
| van Gulik, TM | 1 |
| van Hooft, JE | 1 |
| van Laarhoven, HW | 1 |
| Martin, RC | 1 |
| Schoorlemmer, A | 1 |
| Lièvre, A | 1 |
| Ouine, B | 1 |
| Canet, J | 1 |
| Cartier, A | 1 |
| Amar, Y | 1 |
| Cacheux, W | 1 |
| Mariani, O | 1 |
| Selves, J | 1 |
| Guyetant, S | 1 |
| Bieche, I | 1 |
| Berger, F | 1 |
| de Koning, L | 1 |
| Vigano, L | 1 |
| Darwish, SS | 1 |
| Rimassa, L | 1 |
| Cimino, M | 1 |
| Carnaghi, C | 1 |
| Donadon, M | 1 |
| Procopio, F | 1 |
| Personeni, N | 1 |
| Del Fabbro, D | 1 |
| Santoro, A | 1 |
| Torzilli, G | 1 |
| Odawara, S | 1 |
| Kitajima, K | 1 |
| Katsuura, T | 1 |
| Kurahashi, Y | 1 |
| Shinohara, H | 1 |
| Yamakado, K | 1 |
| Lowe, NM | 1 |
| Kershaw, LE | 1 |
| Bernstein, JM | 1 |
| Withey, SB | 1 |
| Mais, K | 1 |
| Homer, JJ | 1 |
| Slevin, NJ | 1 |
| Bonington, SC | 1 |
| Carrington, BM | 1 |
| West, CM | 1 |
| Berardi, G | 1 |
| De Man, M | 1 |
| Laurent, S | 1 |
| Smeets, P | 1 |
| Tomassini, F | 1 |
| Ariotti, R | 1 |
| Hoorens, A | 1 |
| van Dorpe, J | 1 |
| Varin, O | 1 |
| Geboes, K | 1 |
| Troisi, RI | 1 |
| Jonker, DJ | 1 |
| Tang, PA | 1 |
| Kennecke, H | 1 |
| Welch, SA | 1 |
| Cripps, MC | 1 |
| Asmis, T | 1 |
| Chalchal, H | 1 |
| Tomiak, A | 1 |
| Lim, H | 1 |
| Ko, YJ | 1 |
| Chen, EX | 1 |
| Alcindor, T | 1 |
| Goffin, JR | 1 |
| Korpanty, GJ | 1 |
| Feilotter, H | 1 |
| Tsao, MS | 1 |
| Theis, A | 1 |
| Tu, D | 1 |
| Seymour, L | 1 |
| Delgado-Ureña, M | 1 |
| Ortega, FG | 1 |
| de Miguel-Pérez, D | 1 |
| Rodriguez-Martínez, A | 1 |
| García-Puche, JL | 1 |
| Ilyine, H | 1 |
| Lorente, JA | 1 |
| Exposito-Hernandez, J | 1 |
| Garrido-Navas, MC | 1 |
| Delgado-Ramirez, M | 1 |
| Serrano, MJ | 1 |
| da Silva, WC | 1 |
| de Araujo, VE | 1 |
| Lima, EMEA | 1 |
| Dos Santos, JBR | 1 |
| Silva, MRRD | 1 |
| Almeida, PHRF | 1 |
| de Assis Acurcio, F | 1 |
| Godman, B | 1 |
| Kurdi, A | 1 |
| Cherchiglia, ML | 1 |
| Andrade, EIG | 1 |
| Dohan, A | 1 |
| Gallix, B | 1 |
| Guiu, B | 1 |
| Le Malicot, K | 1 |
| Reinhold, C | 1 |
| Soyer, P | 1 |
| Bennouna, J | 2 |
| Ghiringhelli, F | 1 |
| Barbier, E | 1 |
| Boige, V | 1 |
| Taieb, J | 1 |
| François, E | 2 |
| Phelip, JM | 1 |
| Borel, C | 1 |
| Seitz, JF | 1 |
| Jacquot, S | 1 |
| Ben Abdelghani, M | 2 |
| Khemissa-Akouz, F | 1 |
| Genet, D | 1 |
| Jouve, JL | 1 |
| Rinaldi, Y | 1 |
| Desseigne, F | 1 |
| Texereau, P | 1 |
| Suc, E | 1 |
| Lepage, C | 1 |
| Aparicio, T | 1 |
| Hoeffel, C | 1 |
| Cubillo, A | 1 |
| Rodriguez-Pascual, J | 1 |
| López-Ríos, F | 1 |
| Plaza, C | 1 |
| García, E | 1 |
| Álvarez, R | 1 |
| de Vicente, E | 1 |
| Quijano, Y | 1 |
| Hernando, O | 1 |
| Rubio, C | 1 |
| Perea, S | 1 |
| Sanchez, G | 1 |
| Hidalgo, M | 1 |
| Chen, HM | 1 |
| Lin, JK | 1 |
| Chen, WS | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Lan, YT | 1 |
| Lin, CC | 1 |
| Teng, HW | 1 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Sugihara, F | 1 |
| Sakamoto, A | 1 |
| Ueda, T | 1 |
| Yamaguchi, H | 1 |
| Yasui, D | 1 |
| Mine, T | 1 |
| Kumita, S | 1 |
| Chang, S | 1 |
| Koo, PJ | 1 |
| Kwak, JJ | 1 |
| Kim, SJ | 1 |
| Kotecki, N | 1 |
| Hiret, S | 1 |
| Etienne, PL | 1 |
| Penel, N | 1 |
| Tresch, E | 1 |
| Galais, MP | 1 |
| Michel, P | 1 |
| Dahan, L | 1 |
| Ghiringelli, F | 1 |
| Bedenne, L | 1 |
| Samalin, E | 1 |
| Piessen, G | 1 |
| Peugniez, C | 1 |
| Clisant, S | 1 |
| Kramar, A | 1 |
| Mariette, C | 1 |
| Adenis, A | 1 |
| Basso, M | 1 |
| Dadduzio, V | 1 |
| Ardito, F | 1 |
| Lombardi, P | 1 |
| Strippoli, A | 1 |
| Vellone, M | 1 |
| Orlandi, A | 1 |
| Rossi, S | 1 |
| Cerchiaro, E | 1 |
| Cassano, A | 1 |
| Giuliante, F | 1 |
| Barone, C | 1 |
| Sehdev, A | 1 |
| Cramer, HM | 1 |
| Ibrahim, AA | 1 |
| Younger, AE | 1 |
| O'Neil, BH | 1 |
| Rossius, L | 1 |
| Lerch, MM | 1 |
| von Weikersthal, LF | 1 |
| Decker, T | 1 |
| Kiani, A | 1 |
| Vehling-Kaiser, U | 1 |
| Al-Batran, SE | 1 |
| Heintges, T | 1 |
| Lerchenmüller, C | 1 |
| Kahl, C | 1 |
| Seipelt, G | 1 |
| Kullmann, F | 1 |
| Stauch, M | 1 |
| Scheithauer, W | 1 |
| Held, S | 1 |
| Giessen-Jung, C | 1 |
| Moehler, M | 1 |
| Jagenburg, A | 1 |
| Kirchner, T | 1 |
| Jung, A | 1 |
| Paolicchi, E | 1 |
| Vivaldi, C | 2 |
| De Gregorio, V | 1 |
| Crea, F | 1 |
| Fornaro, L | 2 |
| Masi, G | 1 |
| Loupakis, F | 1 |
| Graziano, F | 1 |
| Ronzoni, M | 1 |
| Ricci, V | 1 |
| Falcone, A | 2 |
| Danesi, R | 1 |
| Pasquini, G | 1 |
| Vasile, E | 1 |
| Caparello, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 1 |
| Petrini, I | 1 |
| DeWitt, JM | 1 |
| Murthy, SK | 1 |
| Ardhanari, R | 1 |
| DuVall, GA | 1 |
| Wallner, G | 1 |
| Litka, P | 1 |
| Daugherty, C | 1 |
| Fowers, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic[NCT02195180] | Phase 2 | 141 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroe[NCT03675737] | Phase 3 | 1,579 participants (Actual) | Interventional | 2018-11-08 | Active, not recruiting | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.[NCT01622543] | Phase 2 | 109 participants (Actual) | Interventional | 2012-10-26 | Completed | ||
| Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma[NCT01900717] | Phase 2 | 102 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029] | Phase 2/Phase 3 | 492 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients[NCT04802954] | 400 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable [NCT01248299] | Phase 2 | 105 participants (Actual) | Interventional | 2011-01-31 | Terminated | ||
| The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody[NCT04466267] | 40 participants (Actual) | Observational | 2017-03-01 | Completed | |||
| A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131] | Phase 2 | 137 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to OncoGel did not show any impact on overall tumor response) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.7 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 10.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.8 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. (NCT03675737)
Timeframe: Up to 33.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 257 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 204 |
An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented. (NCT03675737)
Timeframe: Up to 36.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 776 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 771 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 51.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.0 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 52.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.6 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 60.6 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 43.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 12.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.5 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 13.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 15.7 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
Changes in CEA level from baseline to week 28 during treatment. (NCT01622543)
Timeframe: Baseline and at 28 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | -14209.4 |
| Folfox Plus Bevacizumab | -1107.99 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response Rate =Proportion of (CR + PR) observed over all randomized patients. (NCT01622543)
Timeframe: 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 27 |
| Folfox Plus Bevacizumab | 18 |
Time from randomization to death from any cause or censored at the time of last known alive (NCT01622543)
Timeframe: From date of randomization to death from any cause or censored at the time of last known alive, assessed up to 49 months
| Intervention | Months (Median) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 19.3 |
| Folfox Plus Bevacizumab | 20.0 |
Time from the day of randomization until the first observation of objective disease relapse or progression, or the appearance of new lesions or death due to any cause. If a patient had not relapsed/progressed or died, PFS was censored on the date of last disease assessment defined as the earliest test date of target lesion or non-target lesions (if patient had no target lesions). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01622543)
Timeframe: 19 months
| Intervention | Months (Median) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 7.33 |
| Folfox Plus Bevacizumab | 9.13 |
"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12
| Intervention | percentage of patients (Number) |
|---|---|
| Group 1 | 12.5 |
| Group 2 | 20.0 |
3 reviews available for fluorouracil and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Colorectal N | 2020 |
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Cetuximab; Colorectal Neoplasms | 2018 |
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T | 2016 |
11 trials available for fluorouracil and Response Evaluation Criteria in Solid Tumors
23 other studies available for fluorouracil and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancre | 2021 |
Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2020 |
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetu | 2020 |
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Asian People; Case-Control Studies; Chemotherapy, Adjuvant; | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2020 |
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2020 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2021 |
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studie | 2021 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycyt | 2017 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothe | 2017 |
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cont | 2018 |
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluo | 2018 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2016 |
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |